If you have problems getting access to either of these, please point your GPs to the new Gov UK document below, which lists who is considered Clinically Extremely Vulnerable (CEV) and who are therefore at the highest risk in terms of COVID-19 infection. MDS, CMML and transplant patients are both listed.
https://www.gov.uk/government/publicati ... antibodies
The section you are looking for is extracted below:
Haematological diseases and recipients of haematological stem cell transplant (HSCT)
- allogeneic HSCT recipients in the last 12 months or active graft versus host disease (GVHD) regardless of time from transplant (including HSCT for non-malignant diseases)
- autologous HSCT recipients in the last 12 months (including HSCT for non-malignant diseases)
- individuals with haematological malignancies who have received CAR-T cell therapy in the last 24 months, or radiotherapy in the last 12 months
- individuals with haematological malignancies receiving systemic anti-cancer treatment (SACT) within the last 12 months
- all people who do not fit the criteria above, and are diagnosed with:
- myeloma (excluding monoclonal gammopathy of undetermined significance (MGUS))
- AL amyloidosis
- chronic B-cell lymphoproliferative disorders (chronic lymphocytic leukaemia, follicular lymphoma)
- myelodysplastic syndrome (MDS)
- chronic myelomonocytic leukaemia (CMML)
- myelofibrosis
- all people with sickle cell disease
- people with thalassaemia or rare inherited anaemia with any of the following (the decision to treat these patients will need to be at the individual patient level with input from the
- haematology consultant responsible for the management of the patient’s haematological condition):
- severe cardiac iron overload (T2 * less than 10ms on magnetic resonance imaging)
- severe to moderate iron overload (T2 * greater than or equal to 10ms on magnetic resonance imaging) plus an additional co-morbidity of concern (for example, diabetes, chronic liver
- disease or severe hepatic iron load on MRI)
- individuals with non-malignant haematological disorders (for example, aplastic anaemia or paroxysmal nocturnal haemoglobinuria) receiving B-cell depleting systemic treatment (for example, anti-CD20, anti-thymocyte globulin (ATG) and alemtuzumab) within the last 12 months